OpenAI kills Sora and launches a specialist life sciences model in the same week, Cursor's coding-only bet hits a $50B valuation, and Novo Nordisk locks in domain-specific AI for drug discovery. The pattern is unmistakable: horizontal AI products are getting killed while vertical specialists attract all the money and attention. For anyone building on or with AI, the message is clear — pick a lane or get run over.